Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round — Hadean Ventures Home…
Continue Reading-
Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248
Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248 — Hadean…
Continue Reading -
Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients
Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD…
Continue Reading -
Join Hadean Ventures!
Join Hadean Ventures! — Hadean Ventures Home Portfolio Team Impact Investors News Events Careers Contact…
Continue Reading -
Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin®
Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin® — Hadean Ventures…
Continue Reading -
Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies
Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1…
Continue Reading -
Oncoinvent Announces Progression of Radspherin® to Third Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial
Oncoinvent Announces Progression of Radspherin® to Third Dose Level Cohort in Ongoing RAD-18-001 Phase 1…
Continue Reading -
Pipeline Therapeutics Completes $80 Million Series C Financing
Pipeline Therapeutics Completes $80 Million Series C Financing — Hadean Ventures Home Portfolio Team Impact…
Continue Reading -
Ekspertenes biotekfavoritter i urolige tider, e24.no
Ekspertenes biotekfavoritter i urolige tider, e24.no — Hadean Ventures Home Portfolio Team Impact Investors News…
Continue Reading -
Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS- 248 in patients with systemic sclerosis
Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS- 248 in patients…
Continue Reading